Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tenet Healthcare Corporation — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.2 (market cap $84.31B), while Tenet Healthcare Corporation trades at $262.84 (market cap $20.98B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 4× Tenet Healthcare Corporation's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Tenet Healthcare Corporation for 15 Days on average.
| MRSH | THC | |
|---|---|---|
Market Cap | $84.31B | $20.98B |
Volume | 3,948,947 | 428,008 |
Sector | Financials | Health |
52-Week High | $207.02 | $280.77 |
52-Week Low | $157.32 | $161.37 |
Typical Hold Time | 109 Days | 15 Days |
Enterprise Value | $104.99B | $32.06B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals, with revenue growing to $26.98B in 2025 and net income of $4.16B, supported by consistent earnings beats. Recent news highlights the completion of the Accel Holdings acquisition, potentially enhancing its advisory services footprint. Valuation ratios include a P/E of 21.57 and ROE of 25.72%, indicating solid profitability.
The outlook for MRSH is positive, driven by earnings momentum and strategic acquisitions, but risks include high debt levels and competitive pressures. Analysts maintain a consensus price target of $202.71, suggesting upside potential, though the majority recommend Hold. Investors should weigh growth opportunities against execution risks and market volatility.
Tenet Healthcare (THC) trades at $261.07, up 0.48% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 82.83% gross margins and consistent earnings beats, while trading at attractive valuations including a 10.07 P/E ratio. Recent news highlights upcoming Q3 2026 earnings on October 29th and positive coverage of the company's growth prospects despite surgical volume challenges.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $283.36 consensus target offering 8.5% upside. The healthcare provider shows improving profitability with net margins expected to reach 9.89% in 2026. Key risks include capital allocation sustainability and potential volatility around upcoming earnings, but the combination of value pricing and growth momentum supports a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
